Aditya Kumar, Author at industrialfront - Page 68 of 78

HCLTech to acquire HPE’s Telco Solutions business for up to $160 million

HCLTech wins multi-year IT services contract from Netherlands’ ASN Bank

by Aditya KumarDecember 18, 2025December 18, 2025

Saregama to invest ₹325 crore in Bhansali Productions, eyes majority stake by 2030

Saregama to invest ₹325 crore in Bhansali Productions, eyes majority stake by 2030

by Aditya KumarDecember 18, 2025December 18, 2025

Infosys receives ₹827.5 crore GST penalty demand; says no material financial impact

Infosys receives ₹827.5 crore GST penalty demand; says no material financial impact

by Aditya KumarDecember 18, 2025December 18, 2025

Jio Financial Services appoints Venkata Peri as Group COO

Jio Financial Services appoints Venkata Peri as Group COO

by Aditya KumarDecember 18, 2025December 18, 2025

RBI grants Paytm arm authorisation for offline and cross-border payments

by Aditya KumarDecember 18, 2025December 18, 2025

Mahindra Lifespaces launches ₹1,900-crore housing project in Bengaluru’s Whitefield

Mahindra Lifespaces launches ₹1,900-crore housing project in Bengaluru’s Whitefield

by Aditya KumarDecember 18, 2025December 18, 2025

US FDA flags Sun Pharma’s Baska unit as OAI after inspection

US FDA flags Sun Pharma’s Baska unit as OAI after inspection

by Aditya KumarDecember 18, 2025December 18, 2025

India’s pharmaceutical exports rose 9.4% year-on-year to $30.47 billion in 2024–25, underscoring the sector’s growing global footprint and manufacturing strength, Commerce Secretary Rajesh Agrawal said on Tuesday. Addressing a regional Chintan Shivir on pharmaceutical exports, Agrawal said India’s domestic pharma market, currently estimated at around $60 billion, is expected to nearly double to about $130 billion by 2030, reflecting the industry’s scale and innovation potential �.Press Release_Press Information Bureau(23).PDF NoneIndia is now the world’s third-largest pharmaceutical producer by volume and 14th by value, with over 3,000 companies, 10,500 manufacturing units and more than 60,000 generic brands across 60 therapeutic areas. Indian medicines are exported to over 200 markets, with more than 60% of shipments going to highly regulated destinations—a key indicator of global quality acceptance. The US accounts for roughly 34% of exports, followed by Europe at about 19% �.Press Release_Press Information Bureau(23).PDF NoneThe deliberations, organised by the Department of Commerce with PHARMEXCIL, focused on easing non-tariff barriers, expanding regulatory cooperation and mutual recognition, and strengthening awareness among MSME exporters. Officials also highlighted opportunities arising from recent trade agreements, including the India–UK CETA and the India–EFTA TEPA, which feature zero-tariff provisions expected to boost the competitiveness of Indian generics.The government reiterated its focus on regulatory strengthening, revised GMP implementation, and building a robust life sciences ecosystem spanning R&D, biologics, vaccines and biosimilars to support the next phase of export growth

India’s pharma exports jump 9.4% to $30.47 billion in FY25, domestic market seen doubling by 2030

by Aditya KumarDecember 18, 2025December 18, 2025

Akzo Nobel India receives GST demand order of ₹22.26 lakh from Kerala tax department

Akzo Nobel India receives GST demand order of ₹22.26 lakh from Kerala tax department

by Aditya KumarDecember 16, 2025December 16, 2025

Sterling and Wilson Renewable Energy gets Kenya tax relief; demand cut nearly 50% to ₹26.5 crore

Sterling and Wilson Renewable Energy gets Kenya tax relief; demand cut nearly 50% to ₹26.5 crore

by Aditya KumarDecember 16, 2025December 16, 2025